Introduction {#section5-1178222616685880}
============

Dyslipidemia is one of the most modifiable risk factors for cardiovascular disease (CVD), a significant chronic condition which imposes a substantial burden of morbidity and mortality; it is the leading cause of death worldwide.^[@bibr1-1178222616685880]^ As a result, dyslipidemia has been widely studied for projecting CVD population incidences, identifying CVD high-risk groups and evaluating prevention strategies for reducing individual and population risks. Accurate identification of dyslipidemia in the population is crucial to enhancing the ability to perform epidemiologic studies, including health systems planning, resource allocation, and pharmacoepidemiologic investigations to promote preventive and acute care programs related to CVDs.

Medico-administrative data, recorded according to the International Classification of Disease (ICD) coding system, have increasingly been used in large-scale studies in recent years due to higher accessibilities and lower costs compared with the population-based surveys. These data allow for the passive surveillance of the disease and are available at lower costs compared with active surveillance, particularly in Canada where a centralized government-based structure in health care exists. As the reliability of the findings from such studies depends on the accuracy of the medico-administrative billing data, studies have attempted to assess the reliability of such coding systems. Although the outcomes of these studies have been varied according to the type of data used and the disease under study, inaccuracy of the ICD codes for the purpose of diagnosis of medical conditions is frequently reported.^[@bibr2-1178222616685880][@bibr3-1178222616685880]--[@bibr4-1178222616685880]^

The majority of such studies have been performed on CVDs rather than their risk factors such as dyslipidemia and diabetes. The outcomes of these studies have questioned the sensitivity and specificity of medico-administrative record data in identifying the trends of stroke and CVDs,^[@bibr5-1178222616685880],[@bibr6-1178222616685880]^ although stroke coding has been found to be useful for high-level comparisons, particularly when compared with other diseases.^[@bibr5-1178222616685880]^ ICD codes have been particularly shown to have restricted potentials for patients with dyslipidemia. This has been shown by the result of few previous studies available using secondary data for lipid research. An algorithm developed by an American study reported that 62.3% of patients with dyslipidemia were not recorded by the ICD codes.^[@bibr4-1178222616685880]^ Another study in a large US medical insurance claims database found that only 15% of laboratory-defined patients had a dyslipidemia diagnosis.^[@bibr7-1178222616685880]^ In addition, some studies suggest more than one record of the ICD coding during 2 or 3 years to identify patients with a particular disease condition.^[@bibr8-1178222616685880][@bibr9-1178222616685880]--[@bibr10-1178222616685880]^ One disadvantage of ICD codes for CVDs is the inability to ascertain severity, which is the most important prognostic variable in the surveillance of CVDs. Coding for CVDs risk factors as an alternative, however, has the potential to tackle these limitations and enrich the utility of medico-administrative data for surveillance of CVDs; yet, they have been rarely examined using medico-administrative data, and a handful of such studies on dyslipidemia, the major modifiable risk factor to CVDs, have limitations from being performed using databases that contain no record of other potential identifying markers of dyslipidemia besides the ICD coding, such as the history of lipid-lowering medication use or laboratory lipid levels.^[@bibr7-1178222616685880]^

The recent emergence of electronic medical records (EMRs), however, seems to have eliminated this barrier. Patients' records from a growing number of health providers are being collected in electronic format, which not only provides access to medico-administrative data (eg, ICD codes) but also contain information on medical histories, comorbidities, laboratory test results, and medication use.^[@bibr11-1178222616685880][@bibr12-1178222616685880]--[@bibr13-1178222616685880]^ The regular management of dyslipidemia is conducted using lipid-lowering medications and routine laboratory testing. The structured format of an EMR database would, therefore, be ideal for evaluating the accuracy of medico-administrative records compared with other diagnostic criteria. This study examines the degree to which the ICD codes alone, or in combination with lipid-lowering medication use or laboratory lipid levels, can predict a diagnosis of dyslipidemia relative to laboratory data or a more elaborate criterion standard. This investigation is conducted using the multidisease record surveillance system within the Canadian Primary Care Sentinel Surveillance Network (CPCSSN), which contains the ICD codes and lipid-lowering medication records by primary care physicians as well as a link to laboratory data for every record. This strategy is particularly important because not all of the existing EMR databases have the entire components of criterion standard algorithms to allow for comparison.

Methods {#section6-1178222616685880}
=======

This cross-sectional study was designed using the secondary analysis of data from EMRs of primary care clinics in St. John's, Newfoundland and Labrador (NL), Canada. Records of patients with complete lipid profiles undertaken during January 1, 2009, to December 31, 2010, were included. The records from the clinics in St. John's, NL, can be a good representative of the health records in the province, as more than 40% of the population of NL resides and commutes through the St. John's metropolitan region.

Study database {#section7-1178222616685880}
--------------

The multidisease record surveillance system within the CPCSSN is commonly used for chronic disease surveillance in primary care and for conducting primary care research.^[@bibr14-1178222616685880][@bibr15-1178222616685880]--[@bibr16-1178222616685880]^ This database contains the EMRs of family physicians which are abstracted quarterly and uploaded to a de-identified system to regional and central pan-Canadian databases. An electronic chart abstraction was performed using the EMRs of clinics in St. John's which form part of the NL component of the CPCSSN.^[@bibr13-1178222616685880]^ The data for this study come from three different sections of EMRs:

1.  ICD coding for disease diagnosis which is an AutoFill section of EMR and is completed when the physician selects a disease diagnosis;

2.  Laboratory results, which are electronically linked to the Laboratory Information System database. These data are independent of the EMR and are completed at the laboratory;

3.  Medication prescriptions, which are entered into the EMR by physicians at every visit according to the medication prescribed during the visit.

Study population {#section8-1178222616685880}
----------------

The study population consisted of subjects from the NL component of the CPCSSN database aged 20 years or older. Among the total patients who received health care services during the study timeframe (January 1, 2009, to December 31, 2010), 4400 patients were identified as having had a complete lipid profile taken. Pregnant women were excluded from the analysis ([Figure 1](#fig1-1178222616685880){ref-type="fig"}).

![Study population flow chart.](10.1177_1178222616685880-fig1){#fig1-1178222616685880}

Algorithm development and evaluation {#section9-1178222616685880}
------------------------------------

The algorithm validation/testing was performed in the following steps:

1.  To determine the performance of ICD coding in comparison with laboratory lipid measurements as an "independent criterion standard," ICD coding was compared with the lipid levels from laboratory data.

2.  In the second step, a combination of the three criteria (laboratory lipid levels, ICD codes, and lipid-lowering medication use) was used to develop a "comprehensive criterion standard" algorithm to identify any record of patients with dyslipidemia in our database, as follows:Any ICD of dyslipidemia recorded (ICD code v.9-272);Any laboratory serum measurements of lipid levels deviating from the cutoffs defined by the Canadian guidelines for the diagnosis and management of dyslipidemias ([Table 1](#table1-1178222616685880){ref-type="table"});^[@bibr17-1178222616685880]^Any record of using lipid-modifying medications during the study period.

###### 

Healthy levels of serum lipids for Canadian adults.^[@bibr17-1178222616685880]^

![](10.1177_1178222616685880-table1)

  Lipid component                                Normal levels
  ---------------------------------------------- ---------------------------------------------
  Total cholesterol (TC)                         \<5.2 mmol/L
  Triglycerides (TG)                             \<1.7 mmol/L
  Low-density lipoprotein cholesterol (LDL-C)    \<3.4 mmol/L
  High density lipoprotein cholesterol (HDL-C)   \>1.0 mmol/L for men \>1.3 mmol/L for women

Use of lipid-modifying agents (HMG-CoA reductase inhibitors, fibrates, bile acid sequestrants, nicotinic acid, and other agents) was identified using the text record of the medication name and/or Anatomical Therapeutic Chemical (ATC) codes. Every group was assumed to have dyslipidemia independent of each other. For instance, the patients with normal lipid levels, but with a history of lipid modification use, were categorized as having dyslipidemia because the medication therapy is expected to alter the lipid levels.

Given that the local clinicians had determined that these three criteria would likely detect the significant majority of patients with dyslipidemia in the EMRs, we deemed that the existence of any one or several of these three criteria in an individual would be a criterion standard diagnosis of dyslipidemia. Furthermore, it is common in population screening studies to have results from one or more tests investigating the same condition, none of which can be considered the "criterion standard" alone.^[@bibr18-1178222616685880]^ In addition, the eMERGE network, a consortium of 5 US institutions linked to secure encrypted EMR data that are designed with the aim of identifying disease phenotypes from EMR, suggests the use of the above three criteria to detect the phenotype of low-density lipoprotein cholesterol (LDL-C) dyslipidemia from EMRs.^[@bibr19-1178222616685880],[@bibr20-1178222616685880]^

The performance of ICD coding against this comprehensive criterion standard was then examined. [Table 2](#table2-1178222616685880){ref-type="table"} provides a detailed description of the three indicators, as well as the "criterion standard."

1.  3. The combinations of ICD coding with medication use or laboratory lipid data were compared against the "comprehensive criterion standard."

2.  4. The above analysis was repeated using the national CPCSSN data between 2010 and 2012 to assess the replicability of the findings.

3.  5. In the end, the association of ICD coding with other factors associated with dyslipidemia, including age, sex, diabetes, hypertension, medication use, smoking, and body mass index (BMI), was examined to determine the factors with the most influence on the ICD coding. We assumed that individuals with different demographics and comorbidities may have variable ICD coding accuracy due to the difference in their management.

###### 

Number of patients with dyslipidemia and associated prevalence categorized by algorithm.

![](10.1177_1178222616685880-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            No. of cases   Apparent prevalence (%)
  -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- -------------------------
  *Situation A*\                                           The most recent lipid profile (total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], low-density lipoprotein cholesterol \[LDL-C\], and triglycerides) on an individual showed one component of the lipid profile was not in the normal range as recommended by the Canadian lipid guidelines: total cholesterol \>5.2 mmol/L, HDL-C \<1.0 mmol/L, LDL-C \>3.4 mmol/L, and triglycerides \>1.7 mmol/L (Statistics Canada, 2011; <http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11732-eng.htm>)   3035           69.0
  An abnormal lipid level is reported in laboratory data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  *Situation B*\                                           Any record of using a lipid-modifying agent including statins, fibrates, bile acid sequestrants, nicotinic acid and derivatives, and other lipid-modifying agents during the study period or an Anatomical Therapeutic Chemical Classification System (ATC) code C10 for these lipid-modifying agents, (WHO, 2012---within 2 years before the date the lipid tests were done; <http://www.who.int/classifications/atcddd/en/>)                                                                                        1556           35.4
  The individual is on a lipid-lowering drug                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  *Situation C*\                                           There is a diagnosis of a "disorder of lipid metabolism" (ICD code 272) according to ICD code 272 in the EMR; (<http://icd9cm.chrisendres.com/index.php?action=child&recordid=2055>)                                                                                                                                                                                                                                                                                                                                  1147           26.1
  The individual has a diagnosis of abnormal lipids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *Comprehensive criterion standard*\                      Patients were deemed to have dyslipidemia if they fitted into either one or more of the *Situations* above: (A) had one component of the lipid profile not in the normal range recommended by Canadian lipid guidelines; (B) there was record of using a lipid-modifying agent; (C) had an ICD code 272 diagnosis on record                                                                                                                                                                                           3573           81.2
  Any one or more of A, B, and C above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistical analysis {#section10-1178222616685880}
--------------------

Analysis, using 2 × 2 table formats, was conducted to evaluate the variation in the diagnosis of dyslipidemia. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Kappa agreement, and the area under receiver operating characteristic curve (AUC) were calculated for every algorithm in comparison with the "criterion standard."

*Sensitivity* was defined as the proportion of patients identified by the testing algorithms who had dyslipidemia according to the "criterion standard." *Specificity* was defined as the proportion of patients excluded by the testing algorithms who did not have dyslipidemia according to the "criterion standard." *PPV* was defined as the proportion of patients with dyslipidemia identified by the testing algorithms that were also confirmed by the "criterion standard." *NPV* was defined similarly for patients who did not have dyslipidemia according to the testing algorithms ([Table 3](#table3-1178222616685880){ref-type="table"}). The Kappa agreement was calculated between every testing algorithms and the "criterion standard." The Kappa values of 0 to 0.20, 0.21 to 0.40, 0.41 to 0.60, 0.61 to 0.80, 0.81 to 0.90 and 0.91 to 1.0 indicate poor, slight, fair, good, very good and excellent agreements, respectively.^[@bibr21-1178222616685880],[@bibr22-1178222616685880]^ A receiver operating characteristic (ROC) curve for each algorithm was measured against the "criterion standard." ROC curves were obtained by calculating the sensitivity and specificity of the test and plotting the sensitivity against 1-specificity. AUC of the ROC is a reflection of how reliable the test is in distinguishing between patients with disease and those without the disease.^[@bibr23-1178222616685880]^ The AUCs greater than 0.8 are considered to have high accuracy, whereas an AUC in the range of 0.7 to 0.9 indicates moderate accuracy, 0.5 to 0.7 indicates low accuracy, and 0.5 a chance result.^[@bibr24-1178222616685880]^ Prevalence was estimated according to the number of patients with dyslipidemia identified by each definition. A logistic regression analysis was performed to determine which factors influenced ICD coding for dyslipidemia. The significance of effects was evaluated at α = .05.

###### 

Definitions for sensitivity, specificity, negative predictive value, and positive predictive value.

![](10.1177_1178222616685880-table3)

                                 Criterion standard   
  -------------- --------------- -------------------- --------------------
  ICD code 272   Dyslipidemia    A (true-positive)    B (false-positive)
                 Healthy Lipid   C (false-negative)   D (true-negative)

Sensitivity: *A*/(*A* + *C*) × 100; specificity: *D*/(*D* + *B*) × 100; positive predictive value: *A*/(*A* + *B*) × 100; negative predictive value: *D*/(*D* + *C*) × 100.

All the analyses were conducted using Stata SE 11.2 (Stata Corp., College Station, Texas, USA).

Ethics {#section11-1178222616685880}
------

The Human Research Ethics Authority, Memorial University of Newfoundland, reviewed and approved the study protocol. All the data were de-identified before the analysis.

Results {#section12-1178222616685880}
=======

The EMRs from a total of 4400 patients (mean age, 58.1 ± 14.8 years; 58.8% women) were included in the study. The population had a BMI of 31.1 ± 15.8, 42.3% of whom were present/former smokers. The prevalence of hypertension and diabetes was 33.5% and 15.2%, respectively. Among this population, 3573 patients had dyslipidemia during the study period according to the "comprehensive criterion standard" definition (prevalence of 81.2%). As shown in [Table 2](#table2-1178222616685880){ref-type="table"}, among all patients, 69.0% were diagnosed with dyslipidemia according to the laboratory results (independent criterion standard), 26.1% had an ICD coding for dyslipidemia, and 35.4% had used one or more lipid-lowering medication. The overlap of these three components is shown as a Venn diagram in [Figure 2](#fig2-1178222616685880){ref-type="fig"}.

![Venn diagram of the three components of the criterion standard algorithm.](10.1177_1178222616685880-fig2){#fig2-1178222616685880}

The ICD codes resulted in a poor outcome when compared with the independent criterion standard (serum lipid levels). This analysis led to a sensitivity of 27.0%, specificity of 76.7%, PPV of 71.1%, NPV of 33.1%, a Kappa agreement of 0.02 and an AUC of 0.51.

In the second attempt, ICD coding was compared with the comprehensive criterion standard as shown in [Table 4](#table4-1178222616685880){ref-type="table"}. The diagnostic data alone (ICD coding) led to the lowest sensitivity (32.1%), NPV (25.4%), Kappa agreement (0.151), and AUC (66.1%) compared with the "comprehensive criterion standard."

###### 

Sensitivity, specificity, and predictive values of all combinations of situations A, B, and C compared with comprehensive criterion standard.

![](10.1177_1178222616685880-table4)

            Sensitivity   Specificity   Positive predictive value   Negative predictive value   Kappa value   AUC (95% CI)
  --------- ------------- ------------- --------------------------- --------------------------- ------------- -------------------
  A         85%           100%          100%                        60%                         0.68          0.92 (0.92--0.93)
  B         43%           100%          100%                        29%                         0.23          0.72 (0.71--0.72)
  C         32%           100%          100%                        25%                         0.15          0.66 (0.65--0.67)
  A and B   99%           100%          100%                        98%                         0.99          1.00 (0.99--1.00)
  A and C   94%           100%          100%                        79%                         0.85          0.97 (0.96--0.97)
  B and C   51%           100%          100%                        32%                         0.28          0.76 (0.75--0.76)

Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval.

The ICD coding data, combined with lipid-lowering medication data, also yielded a poor result. This algorithm led to a low sensitivity (51.2%), NPV (32.2%), Kappa agreement (0.283), and AUC (75.6%) ([Table 4](#table4-1178222616685880){ref-type="table"}). The use of the laboratory results ([Table 4](#table4-1178222616685880){ref-type="table"}) had the highest sensitivity (84.9%), NPV (60.6%), Kappa agreement (0.680), and AUC (92.5%) compared with ICD coding or prescription medication use on their own. Combining the laboratory results together with lipid-lowering medication data further increased the sensitivity (99.6%), NPV (98.1%), Kappa agreement (0.988), and AUC (99.8%) ([Table 4](#table4-1178222616685880){ref-type="table"}).

To replicate our results, we assessed the repeatability of our findings using the Canada-wide records of 2010-2012 in a similar approach. This analysis also showed the lowest sensitivity (32.1%), NPV (26.0%), Kappa agreement (0.15), and AUC (0.66) for ICD coding compared with the "comprehensive criterion standard." The ICD coding data, combined with lipid-lowering medication data, also yielded a low sensitivity (51.2%), NPV (32.2%), Kappa agreement (0.28), and AUC (0.76).

Given that the ICD coding was such a poor predictor of dyslipidemia in the EMRs, an additional analysis was conducted using logistic regression to explore which demographic factors and comorbidities may influence the ICD coding for dyslipidemia ([Table 5](#table5-1178222616685880){ref-type="table"}). Results from this analysis showed that patients prescribed lipid-lowering medication were very likely (odds ratio \[OR\], 9.75; 95% CI, 6.82-13.95; *P* \< .001) to have the ICD codes for dyslipidemia.

###### 

Factors associated with ICD coding for dyslipidemia.

![](10.1177_1178222616685880-table5)

  Variable                         Odds ratio (95% confidence interval)
  -------------------------------- -----------------------------------------------------------------------------
                                   ICD code for dyslipidaemia
  Sex (male)                       1.318 (0.943--1.843)
  Aged 41-64 years                 2.921 (1.060--8.050)[\*](#table-fn4-1178222616685880){ref-type="table-fn"}
  Aged ⩾65 years                   4.276 (1.521--12.021)[\*](#table-fn4-1178222616685880){ref-type="table-fn"}
  Hypertension                     1.502 (1.062--2.125)[\*](#table-fn4-1178222616685880){ref-type="table-fn"}
  Diabetes                         1.299 (0.847--1.990)
  Former/current smoker            1.040 (0.876--1.233)
  BMI ⩾30                          1.044 (0.734--1.484)
  Lipid-lowering medication user   9.754 (6.821--13.947)[\^](#table-fn4-1178222616685880){ref-type="table-fn"}

Abbreviations: BMI, body mass index; ICD, International Classification of Disease.

Significant at \**P* \< .05; \^*P* \< .001.

Discussion {#section13-1178222616685880}
==========

This study has demonstrated that using the ICD coding alone is an inaccurate indicator of dyslipidemia. The ICD coding data represented a substantial underestimation of dyslipidemia cases. The use of ICD codes in combination with data from laboratory results or lipid-lowering medication added insignificant marginal value to the respective algorithms. In addition, the ICD coding data alone yielded the most false-negatives. The ICD codes also performed poorly when compared with the serum lipid levels alone as a independent criterion standard. In addition, the case identification for dyslipidemia did not improve when we used one ICD code for a longer duration (during 2 years/during 3 years) or when we used more than one ICD code during 3 years to identify patients with dyslipidemia (data not shown).

Although the ICD codes are reported to be able to accurately identify patients with many medical conditions such as ischemic heart disease,^[@bibr25-1178222616685880]^ diabetes mellitus,^[@bibr26-1178222616685880]^ and preeclampsia,^[@bibr27-1178222616685880]^ their potential for patients with dyslipidemia is restricted. Our results are consistent with the few previous studies available using secondary data for lipid research. In support of our notion regarding the inaccuracy and unreliability of using the ICD coding data for lipid research, we learned that an American study created an algorithm for detecting dyslipidemia and diabetes. The algorithm identified 58.4% of patients with hyperlipidemia, 62.3% of whom were not recorded as having dyslipidemia by the ICD codes.^[@bibr4-1178222616685880]^ Another study in a large US medical insurance claims database found that only 15% of laboratory-defined patients had a dyslipidemia diagnosis.^[@bibr11-1178222616685880]^ In the province of Alberta, Canada, Kokotailo and Hill^[@bibr28-1178222616685880]^ showed that although the medico-administrative billing system is a good indicator of stroke and some of its risk factors including diabetes mellitus and hypertension, the identification of hyperlipidemia is not confidently made where the sensitivity was reported to be 57%. The exact reason for incomplete coding of dyslipidemia is unclear. Kokotailo et al^[@bibr28-1178222616685880]^ considered "a lack of perceived importance by health technologist coders, or a lack of time to code everything," as the putative reason.

The use of advanced technologies in disease coding may be a solution to this problem and to improve the accuracy of ICD codes. Natural language processing, a range of computational techniques for analyzing written or oral texts for the purpose of achieving human-like language processing, has been applied to the EMRs and have shown to improve the accuracy of case definition for inflammatory bowel disease,^[@bibr29-1178222616685880]^ venous thromboembolic disease,^[@bibr30-1178222616685880]^ and cancer.^[@bibr31-1178222616685880]^ Multimodal fusion/interaction are multiple modes of interaction with a system which provides several distinct tools for input and output of data. This technique has been implemented in different aspects of medical diagnosis including the processing of brain imaging^[@bibr32-1178222616685880]^ and magnetic resonance imaging (MRI)^[@bibr33-1178222616685880]^ data, as well as discriminative learning for Alzheimer's disease diagnosis.^[@bibr34-1178222616685880]^ This, however, has rarely been implemented in disease coding and EMR processing. The use of this method might have a potential for improving the disease coding in medical administrative data.

Consideration ought to be given to possible limitations when interpreting and applying these data. The possibility of information bias and data inaccuracy cannot be ignored, despite the fact that the direct link between the Laboratory Information System and EMRs should decrease the probability of data entry errors. Also, these results are based on ICD version 9.0. Newer versions of ICD, including ICD 10.0 and ICD 11.0, have been released. It is notable that the case definition for dyslipidemia does not change considerably between these versions, and thus, the findings of this study can be applied to newer versions of ICD.

One may question the representativeness of the study as this study focused only on the data from EMR clinics in St. John's, NL, Canada, to assess the validity of the ICD coding in identifying patients with dyslipidemia. We assessed the repeatability of our findings using a national dataset. A similar approach was performed using the data from CPCSSN across Canada between 2010 and 2012. This analysis showed the low accuracy of the ICD coding as is seen in this study.

In addition, our data only apply to primary care, and it may not be extended to hospital-based and specialized care where more severe and acute cases of CVDs and dyslipidemia exist.

Conclusions {#section14-1178222616685880}
===========

Using secondary data to identify patients diagnosed with dyslipidemia could involve information on laboratory values, lipid-lowering medication data, or diagnostic data. Often, a given secondary database will have only one of these pieces of information. Results from laboratory data may only have levels of lipids, pharmacy data may only have prescription records, and provincial billing databases may only have diagnostic data. Databases that contain all three of these (lipid levels, medications, and diagnoses) can be used to understand how either one or any two of these pieces of information can predict whether dyslipidemia exists in an individual. The CPCSSN database contains all three of these types of information.

Although the ICD codes have typically been used for the diagnosis of many medical conditions in both research and practice, our research suggests that they are not an accurate indicator of patients with dyslipidemia. Therefore, caution ought to be taken into account when using the databases established according to the ICD codes for research involving dyslipidemia.
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